Introduction
Cirrhosis has long been recognized by the development of acute deterioration of liver and/or renal function, hepatic encephalopathy and high risk of hospital mortality in association to a precipitating event, commonly an infection [1] [2] [3] . During the last decade many experts have suggested that this array of symptoms may constitute the hallmark of a new specific entity. The term acute-on-chronic liver failure (ACLF) has gained popularity for this condition [4] [5] [6] . Since current diagnostic criteria of ACLF are based on personal opinions rather than on objective data, significant discrepancies between groups are apparent [7] [8] [9] . Due to these discrepancies, the first project of EASL-Chronic Liver Failure (CLIF) Consortium was to perform a prospective observational investigation (CANONIC Study) in a large series of patients with cirrhosis (1343 cases). These patients were consecutively admitted to 21 European hospitals for the treatment of an acute decompensation (AD). The aim was to assess the concept, prevalence, diagnostic criteria, precipitating events, natural course and prognosis of ACLF. The current review is largely based on this investigation [10, 11] .
• ACLF is a specific syndrome characterized by acute decompensation (AD), organ failure (OF) and high short-term mortality. AD means development of ascites, encephalopathy, gastrointestinal hemorrhage and/or bacterial infections. OFs (liver, kidney, brain, coagulation, respiration, circulation) are defined by the original CLIF-SOFA score or its simplified version CLIF-C OF score. High short-term mortality means a 28-day mortality rate ≥15%
• Patients with single OF have different 28-day mortality according to the type of OF and the presence of renal dysfunction (serum creatinine 1.5-1.9 mg/ dl) and/or cerebral dysfunction (grade 1-2 hepatic encephalopathy). 1. Patients with liver, coagulation, respiration or circulation failure and no cerebral and/ or renal dysfunction have low mortality rate (5-7%) and therefore no ACLF; 2. Patients with cerebral failure (grade 3-4 hepatic encephalopathy) but no renal dysfunction also have low mortality (8%) and no ACLF; 3. Finally, patients with renal failure (serum creatinine ≥2 mg/dl), those with cerebral failure and renal dysfunction, and those with liver, coagulation, respiration or circulation failure, and renal and/or cerebral dysfunction have a mortality rate of 16-30% and ACLF. The presence of one OF is, therefore, not a synonym of ACLF
• Mortality in ACLF correlates with the ACLF grade: ACLF-1 is associated to a 28-day mortality rate of 22%, ACLF-2 (2 OFs) of 32% and ACLF-3 (3-6 OFs) of 73%. Mortality rate in patients without ACLF is 4.9%
• The prevalence of ACLF in patients hospitalized with AD is 30%, being particularly prevalent in alcoholic and hepatitis B associated cirrhosis. ACLF may develop at any time during the course of cirrhosis and is especially severe in patients without prior history of AD. The most frequent precipitating events associated to ACLF are bacterial infections, active alcoholism or acute reactivation of hepatitis B, but in 40% of cases no precipitating event can be identified
• ACLF is very dynamic. It may improve (50%) or worsen (20%) within a short period of time. Not surprisingly, prognosis is more dependent on the early clinical course than of the initial ACLF grade Definition, prevalence, clinical features and prognosis of ACLF according to the CANONIC study
Methodology used
The following features were pre-defined before the analysis of the CANONIC database:
1. ACLF was defined as a syndrome characterized by AD of cirrhosis associated to organ failure (OF) and high short-term mortality rate.
2. AD refers to the acute development of ascites, hemorrhage, encephalopathy and/or bacterial infections. 3. The sequential Organ Failure Assessment (SOFA) Scale [12] was the model selected for the diagnosis of organ failure because it is widely used in patients requiring intensive care treatment and is superior to the Child-Pugh and MELD scores [13] [14] [15] in predicting mortality in patients with cirrhosis and (OF(s)). Since components of the SOFA score (liver, renal, cerebral, coagulation, circulatory and respiratory function) do not take into account specific features of cirrhosis, the SOFA scale was modified establishing a new scale called the CLIF-SOFA score (CLIF-SOFAs) adapted for liver patients.
A simplified CLIF-SOFA score (CLIF Consortium Organ Failure score, CLIF-C OFs) with identical diagnostic criteria for organ failure and similar prognosis was later designed (Fig. 1A ) [16] . 4. ''Relatively high short-term mortality rate'' was defined as a mortality rate equal or greater than 15% within a period of 28 days. This figure represents approximately 50% of the short-term mortality rate associated with severe sepsis in the general population [17] . The inclusion of a short-term mortality rate threshold in the definition of ACLF was considered important because it has major therapeutic implications. Fig. 1B shows that mortality rate in the CANONIC patients was clearly related to the presence and number of organ failures as defined by the CLIF-SOFA score or by the CLIF-C OFs. Also, renal dysfunction (as defined by a serum creatinine of 1.5-1.9 mg/dl) and/or moderate (grade 1-2) hepatic encephalopathy (cerebral dysfunction), when associated to single organ failure, were found to predict prognosis. Based on the presence of OF, renal and/or cerebral dysfunction, and short-term mortality rate, the following groups of patients were excluded and included from the diagnosis of ACLF: Severity of ACLF was then graded according to the number of OFs: ACLF 1: 1 OF; ACLF 2: 2 OFs; ACLF 3: 3-6 OFs.
The prevalence of ACLF in the CANONIC Study patients was 30% (20% at admission and 10% during hospitalization) and the overall 28-day and 90-day mortality rates were 33% and 51%, respectively. Mortality rates in patients without ACLF were low (28-day: 1.9%; 90-day: 10%). The prevalence, 28-day and 90-day mortality rates associated with the different grades of ACLF were 15.8%, 22%, and 41% respectively in ACLF-1, 10.9%, 32%, and 55% in ACLF-2 and 4.4%, 73%, and 78% in ACLF-3.
Clinical features and precipitating events of ACLF
Patients with ACLF were significantly younger than those without ACLF and the main etiologies were alcoholism in 60%, hepatitis C in 13% and alcoholism plus hepatitis C in 10% (Table 1 ). In only 5% of patients was cirrhosis associated with hepatitis B virus (HBV) infection. The commonest OF in patients with ACLF was renal failure (56%), followed by liver, coagulation, cerebral, circulatory and respiratory failures (44%, 28%, 24%, 17%, and 9%, respectively). The prevalence of circulatory and respiratory failure was significant only in patients with ACLF-3. Patients with ACLF showed systemic inflammation (high count of C-reactive protein and leukocyte concentration) which was independent on the presence or absence of recognized bacterial infections.
The traditional concept that OF(s) and, therefore, ACLF is the final event of a long-standing decompensated cirrhosis was not supported by the CANONIC Study, since almost half of patients with ACLF did not have a prior history of AD or had developed the first AD within the 3 months prior to diagnosis of ACLF (Table 1) . Patients with no history of decompensated cirrhosis developed a more severe form of ACLF than patients with previous episodes of decompensation (28-day mortality of 42% vs. 29%).
The most common precipitating events were bacterial infections and active alcoholism (Table 1) . Interestingly in patients with ACLF the prevalence of alcoholic cirrhosis (60%) was higher than the prevalence of active alcoholism, indicating that alcoholic hepatitis accounts for only part of cases of ACLF associated with alcoholic cirrhosis. There was a small proportion of other precipitating events. As a trigger, gastrointestinal hemorrhage was less frequent in patients with ACLF than in patients without ACLF, suggesting that hemorrhage, if not associated to other complications (i.e. active drinking and/or bacterial infections), is not related to ACLF development. Finally, and of considerable interest is the significant proportion of patients developing ACLF in the absence of any identifiable trigger. Mortality was independent of the presence and type of precipitating events, indicating that although triggers are important in the development of ACLF, mortality depends of other factors, such as the clinical course (see below) and number of OFs.
Clinical course of ACLF
ACLF is an extraordinarily dynamic syndrome [11] and only onethird of ACLF patients grade had no change during hospitalization. In most cases ACLF either improved (50%) or worsened (20%). Resolution of ACLF (no OF) was observed in 40% of patients. The frequency of resolution was high (55%) in patients with ACLF-1, moderate (35%) in patients with ACLF-2 and low (15%) in patients with ACLF-3. Although the ACLF grade at diagnosis correlated with prognosis, the clinical course of the syndrome during hospitalization was the most important determinant of short-term mortality. In fact, 28-day survival in patients developing resolution of ACLF was similar than that in patients with AD without ACLF. Since changes in ACLF grade occurred very rapidly (1-2 days) or rapidly (3-7 days) in most patients, the early course of ACLF was a major determinant of prognosis.
ACLF in patients with cirrhosis associated to HBV infection
Li et al. have reported the characteristics of ACLF in 890 consecutive patients with HBV associated-cirrhosis and AD using the diagnostic criteria derived from the CANONIC Study [18] . Their results indicate that ACLF associated to HBV infection is similar to ACLF associated to alcoholism or chronic hepatitis C although with some specific characteristics. The prevalence of ACLF in the Chinese study was higher (40%) than in the CANONIC series, with ACLF-2 being the most frequent ACLF grade, followed by ACLF 1 and 3. Liver and coagulation failures were the most common OFs. The most frequent precipitating event was bacterial infections followed by reactivation of hepatitis B and active alcoholism. In half of patients no precipitating event could be identified. As in the CANONIC Study, patients with ACLF showed systemic inflammation independently on the type of precipitating event. Mortality rates (28-day and 90-day) in patients with no ACLF, ACLF and ACLF grades 1, 2, and 3 were similar to those in CANONIC series. Fifty-per-cent of patients had no prior AD episodes. Mortality was unrelated to the presence or type of precipitating events or prior history of AD. 
Systemic inflammation as a cause of ACLF
As indicated, white cell count and plasma C-reactive protein (CRP) levels are higher in patients with ACLF than in those without, indicating higher degree of systemic inflammation in the former patients [4] . Furthermore, the higher white cell count or CRP levels the higher the number of failing organs [4] . Together these findings suggest that OFs may result from Data are means ± SD or number of patients (%). a Absence or presence of ACLF at enrolment or during the post-enrolment hospitalization.
b Active alcoholism was defined by more than 14 drinks per week in women and more than 21 drinks per week in men. c Other precipitating event was defined by the presence of one of the following: transjugular intrahepatic porto-systemic shunting, major surgery, therapeutic paracentesis without use of intravenous albumin, hepatitis, or alcoholic hepatitis (liver biopsy required for diagnosis). No precipitating event denotes the absence of bacterial infection, active alcoholism, or other precipitating event. e More than one precipitating event denotes the presence of at least two of these: bacterial infection, active alcoholism, or other precipitating event.
f Kidney dysfunction was defined by serum creatinine levels ranging from 1.5 mg/dl to 1.9 mg/dl. g Mild-to-moderate hepatic encephalopathy is grade I or II hepatic encephalopathy according to the West Haven classification.
an excessive inflammatory response, for which the term immunopathology is used [19] . As shown by studies in type-1 hepatorenal syndrome, a special form of ACLF, and in severe sepsis, immunopathology may cause OF as a consequence of impairment in cardiocirculatory function leading to organ hypoperfusion and/or by direct specific effect of inflammatory mediators on cell function and death. An alternative view is that OFs develop mainly because of an impairment of mechanisms involved in tissue homeostasis. The distinction between these two arms of the alternative is crucial, for example in the context of infection. If an excessive immune response to the pathogen is the cause of OF, the use of anti-inflammatory therapies could be effective. In contrast, if the primary mechanism of OF is an alteration of tissue homeostasis caused directly by the pathogen, the use of anti-inflammatory therapies may decrease the immune response (which is in fact beneficial to reduce pathogen burden), fail to restore tissue homeostasis and finally worsen the outcome of the infection. Table 2 ). The engagement of PRRs results in the activation of signaling cascades that activate transcription factors (e.g., nuclear factor (NF)-jB, AP-1, interferon (IFN)-regulator factor (IRF) 3, among others) [20, 21] . These induce hundreds of genes including those encoding major inflammatory cytokines [7, 22, 23] ( Fig. 2A and B) . This inflammatory response is beneficial in that it plays a major role in host resistance to infection, i.e. the reduction of bacterial burden [19] . However, the inflammatory response to bacterial components may be excessive and associated with collateral tissue damage (immunopathology) resulting in OF [19] .
Key Points 2
Effects of an excessive inflammatory response. Patients with this excessive response have severe sepsis or septic shock [20] . Bacterial components and proinflammatory cytokines are known to induce the inducible nitric oxide (NO) synthase in arteriolar walls of the systemic circulation and on cardiac tissue resulting in increased production of the vaso-relaxant NO, impairment in cardiac inotropic function, arterial hypotension and decreased oxygen delivery to tissues [20, 24] . Bacterial components and proinflammatory cytokines target the endothelium of microvasculature in vital organs favoring the formation of microthrombi (and tissue hypoxia) as well as adhesion and transendothelial migration of various circulating cells [25] . Influx of phagocytes in tissues may induce tissue damage (cell dysfunction, apoptosis or necrosis) via release of oxygen reactive species [25] . All these features contribute to OFs.
Late stage
A proportion of patients who survive the early stage of bacterial infections progress to an immune suppressed state [26] . Immune suppression is characterized by decreased production of inflammatory cytokines, decreased HLA-DR expression at the surface of antigen-presenting cells, high risk of hospital-acquired bacterial infections, and infections by reactivated viruses such as cytomegalovirus or herpes simplex virus and poor prognosis.
Bacterial infections in cirrhosis. Organ failures related to immunopathology
Early stage Evidence for an excessive innate immune response in cirrhosis.
During the first hours of bacterial infection, patients with cirrhosis have significantly higher plasma levels of proinflammatory cytokines than patients without cirrhosis [27] . Experimental studies investigated the in vivo effects of a challenge with lipopolysaccharide (LPS, a PAMP recognized by TLR4 (Table 2) ) and found that LPS-induced plasma TNF-a levels were significantly higher in cirrhotic than in non-cirrhotic animals [28] [29] [30] . Interestingly in freshly isolated monocytes or peripheral blood mononuclear cells (PBMCs), the ex vivo LPS-stimulated production of proinflammatory cytokines and chemokines is higher in cells from patients with cirrhosis than in cells from healthy subjects [23, [31] [32] [33] [34] [35] [36] . The mechanisms of the ''cytokine storm'' associated with cirrhosis are poorly understood and need to be investigated further.
Is there a role for an excessive inflammatory response in the development of organ failures in cirrhosis? In patients with spontaneous bacterial peritonitis (SBP) higher levels of proinflammatory cytokines in the plasma and ascitic fluid are associated with an increased risk of renal failure [37] The degree of the ex vivo LPS induction of proinflammatory genes in PBMCs from patients with decompensated cirrhosis is related to prognosis: the higher the gene induction the higher the risk of short-term death [23] . ACLF is the main cause of death in patients with cirrhosis [4] . Together these findings suggest that patients with cirrhosis who have innate immune cells with super-inducible proinflammatory genes are at risk of developing ACLF.
Late stage
Evidence of immune suppression has been reported in some patients with bacterial infection-induced ACLF [38] .
Patients had decreases in monocyte HLA-DR expression and ex vivo TNF-a production by LPS-stimulated monocytes [38] . These findings suggest that patients were investigated several days or weeks after their admission to the hospital, and there is no clear information on the in-hospital risk of bacterial infection or viral reactivation in patients with ACLF.
Organ failures related to alterations in tissue homeostasis in the general population and cirrhosis Direct tissue damage by bacteria Bacterial virulence can be due to direct damage to host's tissues by toxins and virulence factors. Bacterial products alter tissue homeostasis through different inhibitory mechanisms affecting translation, electron transport chain (resulting in mitochondrial oxidative stress), protein folding in the endoplasmic reticulum (ER) lumen (resulting in ER stress), tRNA synthetases, actin cytoskeleton, among others (Table 3 ) [19] .
There is currently no information on the direct tissue damage caused by bacteria as a mechanism for OFs in patients with cirrhosis. 
Failed tolerance
As mentioned earlier, infection may be associated with two fitness costs: first, the immune response to infection can be excessive and cause tissue damage; second bacteria can directly damage tissues [19] . The host can reduce fitness costs through tolerance mechanisms that reduce tissue damage caused by the host immune response or directly by bacteria [19] . Some tolerance mechanisms are listed in Table 3 . These findings suggest that failed tolerance can play a role in the development of OF caused by bacterial infection. To address this hypothesis Medzhitov and colleagues used a mouse model of lethal viral (influenza virus)-bacterial (L. pneumophila) coinfection [6] . In this model, co-infection results in lung failure and death. The authors show that lung failure is related to marked downregulation of a battery of genes including genes involved in tissue and cellular repair and lung development as well as genes involved in stress responses in lung tissue. Importantly, in this model there was no evidence for tissue damage caused by the immune response of the host [6] . This is an example of organ damage cause by failed tolerance.
Little is known about organ tolerance in the context of sepsis in cirrhosis. In a rat model of LPS-induced sepsis, LPS via TNF-a induced in vivo apoptosis of 30-40% of hepatocytes in cirrhotic livers, an effect not observed in normal rats [29] . TNF-a elicited hepatocyte apoptosis because the translation of NF-jB-survival genes into proteins was inhibited in these cells [29] . The blockade of translation of NF-jB-target genes was related to sustained phosphorylation of eukaryotic initiation factor a caused by chronic ER stress in cirrhotic hepatocytes [29] . Failed tolerance may therefore explain LPS-induced hepatocyte death in these cirrhotic livers (Fig. 2C) .
Inflammation unrelated to infection
The trigger of ACLF is not related to an infection in 70% of cases [1] . In these cases inflammation is present and might be induced by PAMPs or endogenous ligands for TLRs.
Role of PAMPs
Patients with cirrhosis have translocation of intestinal Gramnegative bacteria [39] . In a proportion of patients whole bacteria do not reach the systemic circulation and infection does not 
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No mRNA translation TNF-α-induced APOPTOSIS occur. However these bacteria may release PAMPs that reach the liver and systemic circulation. PAMPs may thus be recognized by PRRs and trigger inflammation ( Table 2 ). There is evidence of an LPS contribution to liver inflammation and injury in patients with severe alcoholic hepatitis [40] . The involvement of PAMP-induced inflammation in the development of extra-hepatic OFs deserves investigation.
Fig. 2. Induction of inflammation and its consequences on hepatocyte survival in cirrhotic livers. (A) Induction of the innate immune response by E. Coli lipopolysaccharide (LPS
Endogenous ligands for TLRs
The fact that TLRs are able to recognize not only PAMPs but also endogenous molecules (produced by the host) has been shown in experiments in non-cirrhotic individuals. These molecules can be released by dying cells and include the danger/damage-associated molecular pattern (DAMP) high-mobility group box 1 (HMGB1) and products of the extracellular matrix (such as biglycan, hyaluronic acid, versican, extradomain A of fibronectin and surfactant protein A). These endogenous ligands may be recognized by cell surface TLRs (TLR2, TLR4) and induce ''sterile'' inflammation ( Fig. 2B ) [41] . Dying cells are also known to release heat shock proteins and some of these proteins have also been shown to induce inflammation through cell surface TLRs [41] .
Finally there are examples of TLR-mediated recognition of self nucleic acids (Table 1 ). This recognition is inappropriate and may lead to inflammation [28] . Cell death or oxidative stresses are common findings in patients with ACLF. Therefore future studies performed in the context of ACLF should seek for endogenous ligands of TLRs and investigate their role in inflammation and the development of OFs.
ACLF is a complex syndrome because it is the result of a complex mechanism
The above discussion implies that systemic inflammation in ACLF has a complex pathogenesis. The release of PAMPs by bacteria is important but the syndrome occurs in the setting of bacterial infections in only one-third of patients [10] . Translocation of PAMPs without viable bacteria from the intestinal lumen to the systemic circulation or the release of DAMPs by dying cells during acute liver injury (i.e. acute alcoholic liver injury or reactivation of hepatitis B) or increased systemic oxidative stress are likely mechanisms of the ''sterile inflammation'' observed in most patients with ACLF. Finally, acute increase in systemic inflammation may not be the sole mechanism. It is important to note that ACLF develops in patients with AD, who already have moderate systemic inflammation and oxidative stress. Direct tissue damage caused by bacterial products or any process leading to a decrease in the tolerance to inflammation could enhance the effects of this moderate systemic inflammation and precipitate ACLF. These three mechanisms, which are not mutually exclusive but may operate simultaneously, could explain many features observed in patients with AD and ACLF such as the distinct predisposition to develop ACLF and severity of ACLF between patients in front of an identical precipitating event (i.e. higher ACLF severity in patients without prior AD) and the distinct clinical course (resolution, improvement, steady course or worsening) following an identical treatment. Also it could account for the effectiveness of human serum albumin in the prevention and treatment (in combination with terlipressin) of type-1 HRS, a special form of ACLF, owing to the capacity of albumin molecule to bind and decrease the biological effects of PAMPs, vasodilators released in systemic inflammation (NO and prostaglandins) and reactive oxygen species.
Key Points 3
• The CLIF-SOFA and its simplified version CLIF-C OF scores, which are based in the stratification of the function of six organs (liver, kidney, brain, coagulation, circulation and respiration) in 5 (0-4) and 3 (1-3) subscores, respectively, (aggregated scores 0-24 and 3-9, respectively) were initially designed for the diagnosis of OF in cirrhotic patients with AD
• Two other specific prognostic scores, one for patients with ACLF (CLIF-C ACLF score) and a second for patients with AD cirrhosis without ACLF (CLIF-C AD score) that improve the prediction accuracy of the CLIF-C OF score and CLIF-SOFA, MELD, MELD-Na and Child-Pugh scores were subsequently designed.
The CLIF-C ACLF score includes the CLIF-C OF score, age and white cell count. The CLIF-C AD score includes age, white cell count, serum sodium, serum creatinine and INR. Variables in each score were combined to generate a score system ranging from 0 to 100. The CLIF-C OF score, the CLIF-C ACLF score and the CLIF-C AD score allow a step-wise algorithm for a rational management of patients with decompensated cirrhosis
• The general management of ACLF includes a rapid identification and treatment of potential triggers, the application of measures that prevent progression of the syndrome and the use of specific organ support systems. In general, patients with ACLF should be treated in an ICU environment and potential candidates for liver transplantation should be transferred to a transplant center. Liver transplantation is treatment of choice. One year survival after transplantation is of approximately 80%
• Extracorporeal liver support systems based on albumin dialysis have been widely used in patients with ACLF. They have been shown to be effective in supporting organ function in patients with cerebral and renal failure. However they did not improve survival. Plasma exchange, which increases survival in patients with acute liver failure, is being explored in patients with ACLF. Finally, studies on the role of bioartificial livers using hepatocytes are underway. ACLF represents a unique condition to explore the potential effectiveness of new treatments such as granulocyte colony-stimulating factor or cell (hepatocytes or stem cells) transplantation
Prognostic assessment of patients with AD of cirrhosis with and without ACLF. Therapeutic implications
To develop management strategies for AD patients with or without ACLF, a validated clinical scoring system that can be used at the bed-side is required that can be updated on a daily basis to allow on-going stratification of patients for intensive care, fasttrack listing for liver transplantation, early hospital discharge or determination of futility of further intensive care [9, 10, 15, 42] .
Many previous studies have defined potential prognostic markers in the cirrhotic patients with OF but for the most part these studies have not been conducted with a view to defining prognostic variables, are retrospective, have performed studies in specific groups of patients or are not validated in independent cohorts [15, [43] [44] [45] [46] . Despite limitations, these previous studies have pointed to the importance of OF in defining the prognosis of the sick cirrhotic patients and suggested the importance of systemic inflammation. In order to overcome these limitations, one of the major objectives of the CANONIC Study was to develop a scoring system for patients with AD of cirrhosis with and without ACLF and a step-wise algorithm for a rational indication of therapy.
Development of a scoring system for patients diagnosed as having ACLF
The approach used was to perform statistical analysis of clinical and biochemical factors in the CANONIC patients with ACLF that were independently associated with mortality and then to mathematically develop a prognostic model [17] . The factors independently associated with mortality were the CLIF-C OF score, age and white cell count. The final model including these three variables was developed to generate a new score (CLIF Consortium ACLF score, CLIF-C ACLFs), which ranged from 0 to 100. The concordance index as well as the AUC of the ROC curve showed that this score was significantly better at predicting the 28-day, 90-day, 180-day and 365-day mortality compared with the current gold-standards; the Model for End-Stage Liver Disease score (MELDs) [47] , MELD-Sodium score (MELD-Nas) [48] , and the Child-Pugh score (CPs) [49] (Table 4 upper panel, Fig. 3A and B) . The CLIF-C ACLFs was then tested and validated for sequential use with data obtained from patients at 48-h, between day 3 and 7 and beyond. The performance of the score improved significantly at predicting 28-day and 3-month mortality of patients when measured at 48 h compared with the measurements at the time of admission suggesting that the CLIF-C ACLF score can be updated on a daily basis taking into account the effect of interventions.
Development of a scoring system for patients diagnosed as having AD but no ACLF Using a similar approach, the CLIF-C Acute Decompensation score (CLIF-C ADs) was developed for hospitalized cirrhotic patients without ACLF using the CANONIC data [50] . The reason for undertaking this analysis was based on the hypothesis that within the no ACLF patients with AD, there is likely to be a very low risk group that should be discharged and there may be a high risk group that will progress to develop full-blown ACLF and therefore have a high mortality. The analysis revealed five independent variables including age, serum sodium, white cell count, creatinine and INR. Depending upon the relative weights, they were combined into a score ranging from 0 to 100. The CLIF-C ADs performed significantly better than the MELDs, MELD-Nas, and the Child-Pugh scores in predicting 3-month and 12-month mortality (Table 4 lower panel, Fig. 3C and D) . In real terms, the CLIF-C ADs improved prediction of mortality by 10-20% over these other scoring systems. Additionally, discrete cut-offs were developed for CLIF-C ADs such that a score of less than or equal to 45 was associated with a 3-month mortality of 1.8% identifying a very low risk group. The score also identified a high risk group that had a score 60 or above that had a 3-month mortality of about 31%. The intermediate risk group was identified by a CLIF-C AD score of greater than 45 but less than 60.
Development of a step-wise algorithm to determine the prognosis of all hospitalized patients with AD
These three scores specifically designed for patients with and without ACLF can be combined into an algorithm that should be useful in defining the prognosis of cirrhotic patients admitted to the hospital on a daily basis [50] . CLIF-C OFs scores should be applied to the patient admitted acutely to the hospital if they have developed a complication of cirrhosis such as encephalopathy, bleeding, infection or ascites. If the score suggests they have ACLF, they should be managed in an enhanced care or intensive care environment. Their prognosis can be determined using the CLIF-C ACLFs, which can be updated daily. The score can be used to gauge the effectiveness of intervention or futility within 3-7 days. On the other hand if they do not have ACLF, then the CLIF-C ADs should be applied. At the outset, those with CLIF-C ADs of less than or equal to 45 may be discharged early from the hospital, those with a score above 60 are at high risk of progressing to ACLF and should therefore be managed in enhanced or intensive care, and those with a score greater than 45 but less than 60 need to be managed in the hospital (Fig. 4) . Although these scores are important to allow future studies, there is a scope CLIF-C ACLF score for improvement as the best predictability reached is a C-index in the range of 0.75.
Management of ACLF
General management
The main principle of the general management of patients with ACLF is an early identification of the syndrome and its potential triggering factors. Although not proven, it is likely that an early identification and treatment of, for example, a SBP in a patient with cirrhosis and ACLF may have a beneficial impact on patient's outcome by preventing/slowing a further progression of ACLF. In general, patients with ACLF should be treated in enhanced care or intensive care units for best monitoring and management [42, 51] . Potential candidates for transplantation should be transferred to a transplant centre. Organ function should be monitored frequently and treatment should be given according to each specific dysfunction. Circulatory and lung support should be provided if there is significant reduction in arterial pressure and arterial oxygenation, respectively. Kidney function should be monitored by means of urine volume and daily serum creatinine concentration.
In case of circulatory failure or kidney failure, fluid resuscitation should be performed cautiously to avoid problems related to an excessive fluid administration such as peripheral edema or, more importantly pulmonary, edema. A trial of plasma expansion with albumin or crystalloids should be made for a limited period of time and then stopped if there is no beneficial effect in terms of improvement of circulatory or kidney function. It is important to remark that most patients with cirrhosis and ACLF have impaired sodium excretion and the fluid administered is usually retained and may cause significant edema and dilutional hyponatremia. Brain function should be evaluated frequently and hepatic encephalopathy should be treated promptly. Intubation should be performed in patients with hepatic encephalopathy grades III or IV to prevent aspiration. Finally, liver function tests, particularly serum bilirubin and prothrombin time should be measured daily.
Specific management
In this section, the potential usefulness of some therapeutic options is discussed in the light of the available evidence.
Liver transplantation
Liver transplantation is a useful method for treating patients with ACLF [52] [53] [54] . Nonetheless, it should be noted that not all patients with ACLF are transplant candidates for a number of reasons, which may include advanced age, active alcoholism, or concomitant diseases, and that the presence of associated OFs, particularly if the number is high or they are severe, may preclude transplantation, at least for a certain period of time until multiorgan dysfunction has improved. Available information on liver transplantation for ACLF patients' is limited [52] [53] [54] . One year survival after transplantation is of approximately 80%, slightly lower but not significantly different from that of patients transplanted without ACLF. However, published studies are retrospective, have a limited sample size, and have used variable definitions of ACLF. Most importantly, only one study used intention-to-treat analysis and showed that some potential candidates are not even listed for transplantation and out of those listed mortality is of 50% [54] . Overall, only one-third of potential candidates reach liver transplantation according to this report. There is therefore a clear need for effective therapeutic methods that can ''bridge'' patients with ACLF to liver transplantation.
Extracorporeal liver support systems
In recent years, several extracorporeal liver support systems have been assessed in the management of ACLF [6, [55] [56] [57] . These systems are based on dialysis techniques aimed at removing a number of substances thought to participate in the pathogenesis of ACLF, such as NO, prostaglandins, PAMPs and reactive oxygen species. The most extensively used system, is the extracorporeal albumin dialysis by the molecular adsorbent recirculating system (MARS). Besides reducing the plasma levels of a number of substances, it has been shown that MARS is effective in improving systemic hemodynamics and severe hepatic encephalopathy. However, a randomized multicentre European study of MARS vs. standard therapy in 189 patients with ACLF did not show differences in survival [57] . Another randomized study using a different system, Prometheus, also showed no improvement on survival [58] . Therefore, although these systems have some beneficial effects in patients with ACLF, their overall usefulness in this setting is uncertain. Along the lines of dialysis systems, plasma exchange has also been proposed as a therapeutic method in patients with acute liver failure and ACLF. A randomized study in patients with acute liver failure showed improved survival in patients treated with plasma exchange compared to a control group receiving standard therapy [59] . A study in patients with ACLF organized by the EASL-CLIF Consortium is underway.
Other methods
A few recent studies have focused their attention on the potential effectiveness of granulocyte colony-stimulating factor (C-CSF) in patients with ACLF [60] [61] [62] . Two randomized studies, one performed mainly in alcoholic patients and the other exclusively in patients with chronic HBV infection, have shown that administration of G-CSF to patients with ACLF reduces the risk of developing kidney and brain failure, and sepsis and improves short-term survival [60, 61] . It is important to note that patients with sepsis, multiorgan failure and/or grade 3 or 4 hepatic encephalopathy were excluded from these studies, which indicates that most of the treated patients had ''early'' ACLF. Potential treatment effectiveness may be related to the mobilization of CD34+ cells from bone marrow to the liver, improvement of neutrophil function, or some other yet unknown factors. Finally, cell transplantation, either using hepatocytes or stem cells, has also been proposed as potential therapy for patients with ACLF with the aim of improving liver function by causing cell repopulation of the diseased liver [63] [64] [65] [66] [67] [68] . Moreover, mesenchymal stem cells have a number of other potentially beneficial effects, including anti-inflammatory actions. So far, however, the available information is limited and a definite conclusion about its potential efficacy in clinical practice cannot be made.
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